UZLeuven Trials - LARVOL Sigma

UZLeuven	Welcome, Profile Billing Logout

51 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Vergote, Ignace B

INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Completed

540

Europe, Canada, US, RoW

NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol

NovoCure Ltd.

Ovarian Cancer

05/23

NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting

160

Europe

Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly

Universitaire Ziekenhuizen Leuven, AstraZeneca

Ovarian Epithelial Cancer

07/21

07/23

NCT03340376 / 2016-000547-14: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting

Europe

Atezolizumab, Doxorubicin

Universitaire Ziekenhuizen KU Leuven, Roche Pharma AG

Cervical Cancer

09/25

Dubois, Christophe LF

HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Recruiting

N/A

Europe, RoW

CLARITY

HighLife SAS

Mitral Regurgitation

12/25

02/31

NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Recruiting

N/A

120

Europe, RoW

HighLife Transcatheter Mitral Valve Replacement

HighLife SAS, ICON plc

Mitral Regurgitation

03/25

06/30

RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruiting

N/A

200

Europe, RoW

Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)

Abbott Medical Devices

Mitral Valve Regurgitation

05/25

05/29

Sinnaeve, Peter R

STREAM-2, NCT02777580 / 2016-001642-26: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Completed

609

Europe, Canada, RoW

Tenecteplase, TNKase, Metalyse, Clopidogrel, Coronary angiography, Primary PCI

KU Leuven, Boehringer Ingelheim, Life Sciences Research Partners, Fund for Clinical Cardiovascular Research at LRD

Myocardial Infarction

10/22

09/23

NCT04431661: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Terminated

N/A

Europe, RoW

Optical Coherence Tomography, Coronary Angiography, Per cutaneous coronary intervention

Ceric Sàrl, Abbott

Out of Hospital Cardiac Arrest

01/23

Vansteenkiste, Johan

PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting

1/2

Europe

PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed

PDC*line Pharma SAS

Non Small Cell Lung Cancer

07/24

12/25

Gillard, Pieter

RADIANT, NCT05923827: Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

Active, not recruiting

N/A

200

Europe

Omnipod 5 System

Insulet Corporation

Diabetes Mellitus, Type 1

08/24

08/25

Adriaenssens, Tom

NCT04591938: FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study

Recruiting

N/A

Europe

Fantom Encore Bioresorbable scaffold implantation

Joost Daemen, Horizon 2020 - European Commission, REVA Medical, Inc.

Percutaneous Coronary Intervention, Myocardial Revascularization, Tomography, Optical Coherence

06/21

12/25

RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

Completed

N/A

307

Europe

Optical Coherence Tomography (OCT)

University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT

In-stent Restenosis

12/22

casteels, kristina m

NCT06452654: Anti-viral Action Against Type 1 Diabetes Autoimmunity

Recruiting

2252

Europe

Comirnaty Injectable Product, Comirnaty 3µg/dose for children for 6 month - 4 years, Sodium Chloride 0.9% Inj, Solution for Injection

Technical University of Munich, Helmholtz Zentrum München, University Hospital Carl Gustav Carus, Kinderkrankenhaus auf der Bult, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Newcastle-upon-Tyne Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Birmingham Women's and Children's NHS Foundation Trust

Diabetes Mellitus, Type 1

10/27

NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting

Europe

Metreleptin

Amryt Pharma

Generalized Lipodystrophy

09/26

SINT1A, NCT04769037: Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

Active, not recruiting

N/A

1149

Europe

B. infantis, Placebo

Helmholtz Zentrum München, Technical University of Munich, Kinderkrankenhaus auf der Bult, University Hospital Carl Gustav Carus, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Medical University of Warsaw, Cambridge Biomedical Campus, Cambridge, UK, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Diabetes Mellitus, Type 1

10/27

Braly, Patricia

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

09/25

08/27

PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed

150

US, RoW

Paclitaxel, Afuresertib, LAE002

Laekna Limited

Platinum-resistant Ovarian Cancer

07/23

06/24

PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

	Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
	Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
	Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
	Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer

Completed

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IMGN853

AbbVie

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

01/24

12/24

NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

	Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
	Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022

Active, not recruiting

125

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin

AbbVie

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

05/26

NIR-OGT-201, NCT05348356 / 2022-001816-25: Nirogacestat in Ovarian Granulosa Cell Tumors

Active, not recruiting

Europe, Canada, US

Nirogacestat, PF-03084014

SpringWorks Therapeutics, Inc., SpringWorks Therapeutics, Inc.

Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer

07/26

12/27

Gerven, Laura H Van

NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry

Recruiting

N/A

4550

Europe

Change Accelerator in Respiratory Care

Chronic Rhinosinusitis (Diagnosis)

06/25

12/25

SPAT_AI, NCT05918354: Development and Evaluation of an Artificial Intelligence Model for the Diagnosis of Aeroallergies

Completed

N/A

993

Europe

Skin Prick Automated Test

Hippocreates

Allergy

09/24

Tack, Jan

MOVE-IT, NCT05621811 / 2021-002254-86: Different Doses of Naronapride Vs. Placebo in Gastroparesis

Recruiting

320

Europe, US

Naronapride, Placebo

Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH

Gastroparesis

09/25

12/25

PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting

Europe, US

Pasireotide Diaspartate, Pasireotide

RECORDATI GROUP

Post-Bariatric Hypoglycemia

04/25

04/26

OCARINA, NCT05740631 / 2020-004180-13: The Effect of Obeticholic Acid in Healthy Volunteers

Recruiting

N/A

Europe

Ocaliva, obeticholic acid, Placebo, Placebo Oral Tablet (Starch)

Universitaire Ziekenhuizen KU Leuven, Intercept Pharmaceuticals

Healthy

07/23

NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Recruiting

N/A

130

Europe

DDI-IBS-001, DDDI-IBS-001 placebo

Biokuris s.a.

Irritable Bowel Syndrome

12/24

Stalmans, Ingeborg

BelGlaucoma, NCT05703724: Prevalence of Glaucoma in Belgium: a Multicenter National Trial

Completed

N/A

1418

Europe

AI algorithm for the detection of glaucoma

Universitaire Ziekenhuizen KU Leuven, Santen Oy

Glaucoma

05/23

Tomassetti, Carla

ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting

380

Europe, US, RoW

OG-6219, Placebo

Organon and Co, Iqvia Pty Ltd

Endometriosis

05/25

Morlion, Bart

NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed

Europe, RoW

AP-325, Placebo

Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH

Peripheral Post-surgical Neuropathic Pain

10/24

Bennett, Johan

OCTOBER, NCT03171311: The Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction

Active, not recruiting

N/A

1201

Europe

Angiographic guided PCI, PCI, percutaneous transluminal coronary angioplasty (PTCA), OCT guided PCI, OCT

Aarhus University Hospital Skejby, Abbott

Ischaemic Heart Disease, Ischemic Heart Disease

03/22

05/29

PINNACLE I, NCT05828173: A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Active, not recruiting

N/A

Europe

LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)

Elixir Medical Corporation

Coronary Artery Disease

04/24

09/24

BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting

N/A

200

Europe

Lithoplasty, Shockwave, Lithotripsy, Conventional

Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.

Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease

09/24

01/25

Tejpar, Sabine

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting

2/3

192

Europe, US, RoW

AL102, Placebo

Immunome, Inc.

Desmoid, Desmoid Tumor

10/25

10/26

AZUR-4, NCT06567782: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Not yet recruiting

120

Europe

Dostarlimab, GSK4057190A, TSR-042, CAPEOX

GlaxoSmithKline

Neoplasms, Colon

09/28

NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting

Europe

Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen

Inspirna, Inc.

Colorectal Cancer, Metastatic Colon Cancer

09/25

12/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting

1/2

374

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

BALLETT, NCT05058937: A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

Recruiting

N/A

936

Europe

Comprehensive genomic profiling

The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx

Solid Tumor, Metastatic Cancer

05/23

05/26

Goffin, Karolien

ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed

300

Europe, Canada, US, RoW

89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)

Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd

Clear Cell Renal Cell Carcinoma

10/22

11/22

Claessen, Guido

ENDURE, NCT05731466: Exercise Right Ventricular Coupling in HFpEF

Recruiting

N/A

Europe

CardioMems HF System, CMR

Universitaire Ziekenhuizen KU Leuven, Abbott

Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension

10/24

12/25

Wauters, Els

PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting

1/2

Europe

PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed

PDC*line Pharma SAS

Non Small Cell Lung Cancer

07/24

12/25

NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting

1/2

Europe, Japan, US, RoW

M1774, Tuvusertib, Cemiplimab

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Non-Small Cell Lung Cancer

05/25

02/26

Bouberhan, Sara

EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting

358

Europe, Canada, US, RoW

Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)

Novartis Pharmaceuticals

Ovarian Cancer

04/23

06/25

NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

	Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
	Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022

Active, not recruiting

125

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin

AbbVie

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

05/26

BEHOLD-1, NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting

240

Europe, Canada, Japan, US, RoW

GSK5733584

GlaxoSmithKline

Solid Tumors, Neoplasms

10/26

07/27

DEKERVEL, Jeroen

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament

Biliary Tract Neoplasms

06/27

06/28

eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting

250

Europe, Canada, Japan, US, RoW

zenocutuzumab (MCLA-128), bispecific, MCLA-128

Merus N.V.

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

12/26

Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting

350

Europe, Canada, US

9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar

Actuate Therapeutics Inc., Actuate Therapeutics Inc

Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma

01/25

01/26

Herpe, Filip Van

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

Devresse, Arnaud

MARIBEL, NCT06677892: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

Recruiting

N/A

Europe

No Intervention

Takeda

Cytomegalovirus (CMV)

08/26

09/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Vergote, Ignace B

INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Completed

540

Europe, Canada, US, RoW

NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol

NovoCure Ltd.

Ovarian Cancer

05/23

NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting

160

Europe

Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly

Universitaire Ziekenhuizen Leuven, AstraZeneca

Ovarian Epithelial Cancer

07/21

07/23

NCT03340376 / 2016-000547-14: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting

Europe

Atezolizumab, Doxorubicin

Universitaire Ziekenhuizen KU Leuven, Roche Pharma AG

Cervical Cancer

09/25

Dubois, Christophe LF

HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Recruiting

N/A

Europe, RoW

CLARITY

HighLife SAS

Mitral Regurgitation

12/25

02/31

NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Recruiting

N/A

120

Europe, RoW

HighLife Transcatheter Mitral Valve Replacement

HighLife SAS, ICON plc

Mitral Regurgitation

03/25

06/30

RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruiting

N/A

200

Europe, RoW

Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)

Abbott Medical Devices

Mitral Valve Regurgitation

05/25

05/29

Sinnaeve, Peter R

STREAM-2, NCT02777580 / 2016-001642-26: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Completed

609

Europe, Canada, RoW

Tenecteplase, TNKase, Metalyse, Clopidogrel, Coronary angiography, Primary PCI

KU Leuven, Boehringer Ingelheim, Life Sciences Research Partners, Fund for Clinical Cardiovascular Research at LRD

Myocardial Infarction

10/22

09/23

NCT04431661: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Terminated

N/A

Europe, RoW

Optical Coherence Tomography, Coronary Angiography, Per cutaneous coronary intervention

Ceric Sàrl, Abbott

Out of Hospital Cardiac Arrest

01/23

Vansteenkiste, Johan

PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting

1/2

Europe

PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed

PDC*line Pharma SAS

Non Small Cell Lung Cancer

07/24

12/25

Gillard, Pieter

RADIANT, NCT05923827: Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

Active, not recruiting

N/A

200

Europe

Omnipod 5 System

Insulet Corporation

Diabetes Mellitus, Type 1

08/24

08/25

Adriaenssens, Tom

NCT04591938: FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study

Recruiting

N/A

Europe

Fantom Encore Bioresorbable scaffold implantation

Joost Daemen, Horizon 2020 - European Commission, REVA Medical, Inc.

Percutaneous Coronary Intervention, Myocardial Revascularization, Tomography, Optical Coherence

06/21

12/25

RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

Completed

N/A

307

Europe

Optical Coherence Tomography (OCT)

University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT

In-stent Restenosis

12/22

casteels, kristina m

NCT06452654: Anti-viral Action Against Type 1 Diabetes Autoimmunity

Recruiting

2252

Europe

Comirnaty Injectable Product, Comirnaty 3µg/dose for children for 6 month - 4 years, Sodium Chloride 0.9% Inj, Solution for Injection

Diabetes Mellitus, Type 1

10/27

NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting

Europe

Metreleptin

Amryt Pharma

Generalized Lipodystrophy

09/26

SINT1A, NCT04769037: Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

Active, not recruiting

N/A

1149

Europe

B. infantis, Placebo

Diabetes Mellitus, Type 1

10/27

Braly, Patricia

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

09/25

08/27

PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed

150

US, RoW

Paclitaxel, Afuresertib, LAE002

Laekna Limited

Platinum-resistant Ovarian Cancer

07/23

06/24

PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

	Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
	Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
	Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
	Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer

Completed

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IMGN853

AbbVie

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

01/24

12/24

NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

	Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
	Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022

Active, not recruiting

125

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin

AbbVie

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

05/26

NIR-OGT-201, NCT05348356 / 2022-001816-25: Nirogacestat in Ovarian Granulosa Cell Tumors

Active, not recruiting

Europe, Canada, US

Nirogacestat, PF-03084014

SpringWorks Therapeutics, Inc., SpringWorks Therapeutics, Inc.

Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer

07/26

12/27

Gerven, Laura H Van

NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry

Recruiting

N/A

4550

Europe

Change Accelerator in Respiratory Care

Chronic Rhinosinusitis (Diagnosis)

06/25

12/25

SPAT_AI, NCT05918354: Development and Evaluation of an Artificial Intelligence Model for the Diagnosis of Aeroallergies

Completed

N/A

993

Europe

Skin Prick Automated Test

Hippocreates

Allergy

09/24

Tack, Jan

MOVE-IT, NCT05621811 / 2021-002254-86: Different Doses of Naronapride Vs. Placebo in Gastroparesis

Recruiting

320

Europe, US

Naronapride, Placebo

Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH

Gastroparesis

09/25

12/25

PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting

Europe, US

Pasireotide Diaspartate, Pasireotide

RECORDATI GROUP

Post-Bariatric Hypoglycemia

04/25

04/26

OCARINA, NCT05740631 / 2020-004180-13: The Effect of Obeticholic Acid in Healthy Volunteers

Recruiting

N/A

Europe

Ocaliva, obeticholic acid, Placebo, Placebo Oral Tablet (Starch)

Universitaire Ziekenhuizen KU Leuven, Intercept Pharmaceuticals

Healthy

07/23

NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Recruiting

N/A

130

Europe

DDI-IBS-001, DDDI-IBS-001 placebo

Biokuris s.a.

Irritable Bowel Syndrome

12/24

Stalmans, Ingeborg

BelGlaucoma, NCT05703724: Prevalence of Glaucoma in Belgium: a Multicenter National Trial

Completed

N/A

1418

Europe

AI algorithm for the detection of glaucoma

Universitaire Ziekenhuizen KU Leuven, Santen Oy

Glaucoma

05/23

Tomassetti, Carla

ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting

380

Europe, US, RoW

OG-6219, Placebo

Organon and Co, Iqvia Pty Ltd

Endometriosis

05/25

Morlion, Bart

NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed

Europe, RoW

AP-325, Placebo

Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH

Peripheral Post-surgical Neuropathic Pain

10/24

Bennett, Johan

OCTOBER, NCT03171311: The Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction

Active, not recruiting

N/A

1201

Europe

Angiographic guided PCI, PCI, percutaneous transluminal coronary angioplasty (PTCA), OCT guided PCI, OCT

Aarhus University Hospital Skejby, Abbott

Ischaemic Heart Disease, Ischemic Heart Disease

03/22

05/29

PINNACLE I, NCT05828173: A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Active, not recruiting

N/A

Europe

LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)

Elixir Medical Corporation

Coronary Artery Disease

04/24

09/24

BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting

N/A

200

Europe

Lithoplasty, Shockwave, Lithotripsy, Conventional

Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.

Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease

09/24

01/25

Tejpar, Sabine

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting

2/3

192

Europe, US, RoW

AL102, Placebo

Immunome, Inc.

Desmoid, Desmoid Tumor

10/25

10/26

Not yet recruiting

120

Europe

Dostarlimab, GSK4057190A, TSR-042, CAPEOX

GlaxoSmithKline

Neoplasms, Colon

09/28

NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting

Europe

Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen

Inspirna, Inc.

Colorectal Cancer, Metastatic Colon Cancer

09/25

12/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting

1/2

374

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

Recruiting

N/A

936

Europe

Comprehensive genomic profiling

The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx

Solid Tumor, Metastatic Cancer

05/23

05/26

Goffin, Karolien

ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed

300

Europe, Canada, US, RoW

89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)

Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd

Clear Cell Renal Cell Carcinoma

10/22

11/22

Claessen, Guido

ENDURE, NCT05731466: Exercise Right Ventricular Coupling in HFpEF

Recruiting

N/A

Europe

CardioMems HF System, CMR

Universitaire Ziekenhuizen KU Leuven, Abbott

Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension

10/24

12/25

Wauters, Els

PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting

1/2

Europe

PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed

PDC*line Pharma SAS

Non Small Cell Lung Cancer

07/24

12/25

NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting

1/2

Europe, Japan, US, RoW

M1774, Tuvusertib, Cemiplimab

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Non-Small Cell Lung Cancer

05/25

02/26

Bouberhan, Sara

EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting

358

Europe, Canada, US, RoW

Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)

Novartis Pharmaceuticals

Ovarian Cancer

04/23

06/25

NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

	Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
	Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022

Active, not recruiting

125

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin

AbbVie

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

05/26

BEHOLD-1, NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting

240

Europe, Canada, Japan, US, RoW

GSK5733584

GlaxoSmithKline

Solid Tumors, Neoplasms

10/26

07/27

DEKERVEL, Jeroen

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

Biliary Tract Neoplasms

06/27

06/28

eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting

250

Europe, Canada, Japan, US, RoW

zenocutuzumab (MCLA-128), bispecific, MCLA-128

Merus N.V.

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

12/26

Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting

350

Europe, Canada, US

Actuate Therapeutics Inc., Actuate Therapeutics Inc

01/25

01/26

Herpe, Filip Van

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

Devresse, Arnaud

MARIBEL, NCT06677892: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

Recruiting

N/A

Europe

No Intervention

Takeda

Cytomegalovirus (CMV)

08/26

09/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites